On 13 May 2026, European Commissioner for International Partnerships Jozef Síkela presented the Global Health Resilience Initiative, a new EU strategy to strengthen global health security. The initiative, adopted by the College of Commissioners on the same day, was first announced by Commission President Ursula von der Leyen in her State of the Union address in September 2025. Síkela framed the initiative as a response to three hard truths: health threats do not respect borders, preparedness pays off, and dependency on a handful of suppliers is dangerous, especially as health is increasingly weaponised for geopolitical purposes.
The initiative outlines five priorities with nine concrete actions. First, it aims for a more effective global health architecture, with the EU stepping up coordination among Member States and pledging funding. Second, it supports country-led health systems through sustainable financing and expertise sharing, focusing on primary health care. Third, it strengthens prevention, preparedness and response to global health threats via global surveillance networks, medical countermeasure availability, and a new global health and resilience tracker. Fourth, it diversifies supply chains by supporting local manufacturing of key health products in partner countries under the Global Gateway framework, promoting partnerships with EU companies. Fifth, it addresses societal resilience by countering disinformation and foreign information manipulation during health crises.
Síkela highlighted the recent Hantavirus outbreak on a cruise ship as a reminder of vulnerability, noting that the frequency and intensity of disease outbreaks are increasing. He stressed that the EU has already mobilised over €6 billion for health up to end 2025, making health a key pillar of Global Gateway investments. The initiative is designed to be practical and targeted, with implementation starting immediately.
Stakeholder impacts EU regulatory bodies: The Commission will take on a stronger coordination role, potentially increasing its influence over global health governance, but may face administrative burden in managing new networks and funding pledges. National authorities of EU member states: They gain from enhanced coordination and funding but may need to align national health strategies with EU-led global priorities, which could limit flexibility. EU pharmaceutical and medical device companies: Opportunities arise from Global Gateway partnerships for local manufacturing in partner countries, but increased supply chain diversification may reduce their dominance in certain markets. Partner countries (non-EU): They benefit from investments in local health infrastructure, skills, and jobs, reducing dependency on external suppliers, but may face conditions tied to EU funding and standards.
Overall, the initiative represents a moderate shift towards EU-led global health governance, balancing public health security with economic opportunities for European industry.
← Atlas › News › Development & Humanitarian Aid